Regenxbio (NASDAQ: RGNX) reported Q2 EPS of ($1.36), $0.24 worse than the analyst estimate of ($1.12). Revenue for the quarter came in at $22 million versus the consensus estimate of $29.02 million.

Financial Guidance:

Based on its current operating plan, REGENXBIO expects its balance in cash, cash equivalents and marketable securities of $593.0 million as of June 30, 2021, to fund its operations, including the completion of its internal manufacturing capabilities and clinical advancement of its product candidates, into the second half of 2023.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.